Targeting LSCs: Peeling Back the Curtain on the Metabolic Complexities of AML

Tian Y Zhang; Ravindra Majeti

doi:10.1016/j.stem.2020.10.007

Targeting LSCs: Peeling Back the Curtain on the Metabolic Complexities of AML

Cell Stem Cell. 2020 Nov 5;27(5):693-695. doi: 10.1016/j.stem.2020.10.007.

Authors

Tian Y Zhang¹, Ravindra Majeti²

Affiliations

¹ Department of Medicine, Division of Hematology, Cancer Institute, and Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford University, Stanford, CA, USA.
² Department of Medicine, Division of Hematology, Cancer Institute, and Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford University, Stanford, CA, USA. Electronic address: rmajeti@stanford.edu.

PMID: 33157042
DOI: 10.1016/j.stem.2020.10.007

Abstract

Most patients with AML succumb to chemoresistant leukemia stem cells (LSCs), which persist and reinitiate disease years after clinical remission. In this issue of Cell Stem Cell, Jones et al. (2020) identify a therapeutically targetable mechanism of resistance to venetoclax in relapsed and refractory AML LSCs mediated by nicotinamide metabolism.

Publication types

Comment

MeSH terms

Bridged Bicyclo Compounds, Heterocyclic
Humans
Leukemia, Myeloid, Acute* / drug therapy
Neoplastic Stem Cells*
Niacinamide
Sulfonamides

Substances

Bridged Bicyclo Compounds, Heterocyclic
Sulfonamides
Niacinamide
venetoclax